Royalty Report: Medical, Device, Therapeutic – Collection: 4306

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Medical
  • Device
  • Therapeutic
  • Disease
  • Spine
  • Supply

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4306

License Grant
Italian Licensor hereby grants to Licensee, an exclusive, worldwide license, with right of sublicense, under Licensor's IP to Commercialize the Products in the Territory. Licensor covenants and agrees with Licensee that during the Term Licensor will not grant any license or similar right with respect to the Products to Commercialize, or to make or have made the Products for sale in the Territory.

Licensor hereby grants to Licensee, and Licensee accepts, an exclusive, license to use Licensor's “EpoSafe” and “Medisulfone” marks and variations of same in the Territory solely in conjunction with the sale and distribution of the Products.

Under the License and Supply Agreement, the Licensor granted to the Licensee an exclusive License, with right of sublicense, to market, promote, distribute, offer for sale and sell the Filtration Products worldwide, excluding Italy for the first three years, during the term of the License and Supply Agreement.

In addition, the Licensee granted to the Italian Licensor an exclusive License under the Licensee's intellectual property to make the Filtration Products during the term of the License and Supply Agreement.

License Property
Licensor develops, manufactures, markets and sells ultrafiltration products based in part upon a proprietary ultrafiltration technology.

Licensor offers several Medisulfone® membranes, one of which is dedicated to blood filtration treatments like hemofiltration and hemoconcentration, while the other provides excellent performances in the ultra-filtration of water requiring high purity fluids for medical use and drinkable water.

An additional advantage of Medisulfone is that it can be disinfected by using chlorine or peracetic acid compounds or the most common disinfecting agents in the dialysis field making for versatility and practicality.

Field of Use
The Licensee will market and sell certain filtration products based upon the Licensor's proprietary Medisulfone ultrafiltration technology in conjunction with the Licensee's filtration products, and will engage in an exclusive supply arrangement for the Filtration Products.

The Licensee has been engaged primarily in the development of hemodiafiltration, or HDF, products and technologies for treating patients with End Stage Renal Disease, or ESRD.

IPSCIO Record ID: 215500

License Grant
The Licensee entered into this agreement with the Italian Licensor which extended the term of the License and Supply Agreement from December 31, 2022 to December 31, 2025, unless earlier terminated by either party in accordance with the terms of the License and Supply Agreement.  In exchange for the rights granted, the Company has agreed to make annual purchases and pay a royalty rate on net sales of the Filtration Products sold.   The original License and Supply Agreement is for the marketing and sale of certain filtration products based upon the Licensor’s proprietary Medisulfone ultrafiltration technology in conjunction with the Company’s filtration products, and to engage in an exclusive supply arrangement for the filtration products.  Licensor granted to the Company an exclusive license, with right of sublicense, to market, promote, distribute, offer for sale and sell the filtration products worldwide, excluding Italy for the first three years, during the term of the License and Supply Agreement.
License Property
Filtration Products are ultrapure water filtration products as a complement to the ESRD therapy business, introducing its proprietary dual stage ultrafilter architecture that address water quality and infection control in both medical and commercial applications.

Licensor manufactures a proprietary hollow fiber polysulfone synthetic membrane for blood and water purification in medical and industrial applications.

Field of Use
This agreement pertains to the drug industry.  The Company develops advanced End Stage Renal Disease (“ESRD”) therapy technology and products. The Company expanded into ultrapure water filtration products as a complement to the ESRD therapy business, introducing its proprietary dual stage ultrafilter architecture. The company has introduced a variety of ultrafiltration and microfiltration products that address water quality and infection control in both medical and commercial applications.

The Company has two products in the hemodiafiltration (“HDF”) modality to deliver therapy for ESRD patients. These are the OLpur mid-dilution HDF filter or “dialyzer,” designed expressly for HDF therapy, and the OLpur H2H HDF module, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy.

ESRD is a disease state characterized by the irreversible loss of kidney function. The Nephros HDF system removes a range of harmful substances more effectively, and with greater capacity, than existing ESRD treatment methods, particularly with respect to substances known collectively as 'middle molecules.' These molecules have been found to contribute to such conditions as dialysis-related amyloidosis, carpal tunnel syndrome, degenerative bone disease and, ultimately, mortality in the ESRD patient. The Nephros Dual Stage Ultrafilter (DSU) is the basis for the Nephros line of water filtration products, which includes the MSU and SSU ultrafilters. The patented dual stage cold sterilization ultrafilter has the capability to filter out bacteria and, due to its exceptional filtration levels, filter out many viruses, parasites and biotoxins.

IPSCIO Record ID: 367343

License Grant
Licensor grants an exclusive, worldwide license under the Patent Rights and any and all related proprietary information, to research, develop, make, import, have made, use, offer for sale, sell and have sold Products and Other Products, including a license to research, develop, make, import, have made, use, offer for sale, sell and have sold Products and Other Products that if used together with other products in a hemofiltration system, a blood filtration circuit, or method of treating patients under those systems.
License Property
Licensor owns rights to certain patents including
Method and System for Colloid Exchange Therapy;
Hemofiltration Systems, Methods and Devices Used to Treat Inflammatory Mediator Related Disease;
Hemofiltration Systems, Methods, and Devices Used for Treatment of Chronic and Acute Diseases; and,
Method and System for Colloid Exchange Therapy.
Field of Use
The field of use is for methods of treating liver failure, multi-organ failure, multi-organ dysfunction syndrome, sepsis, septic shock, systemic inflammatory response syndrome, and related inflammatory disorders by selective blood filtration.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.